Literature DB >> 24838003

BET-ting on chromatin-based therapeutics for heart failure.

Saptarsi M Haldar1, Timothy A McKinsey2.   

Abstract

Studies of transcriptional mechanisms in heart failure have focused heavily on roles of sequence-specific DNA-binding factors such as NFAT, MEF2 and GATA4. Recent findings have illuminated crucial functions for epigenetic regulators in the control of cardiac structural remodeling and mechanical dysfunction in response to pathological stress. Here, we review the current understanding of chromatin-dependent signal transduction in cardiac gene control, and highlight the potential for pharmacologic regulation of BET acetyl-lysine binding proteins as a means of treating heart failure.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BET proteins; Cardiac hypertrophy; Chromatin; Epigenetics; Heart failure; Transcription

Mesh：

Substances：

Year:  2014        PMID： 24838003      PMCID： PMC4115033          DOI： 10.1016/j.yjmcc.2014.05.002

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN： 0022-2828            Impact factor:   5.000


  52 in total

1.  CTIP2 is a negative regulator of P-TEFb.

Authors:  Thomas Cherrier; Valentin Le Douce; Sebastian Eilebrecht; Raphael Riclet; Céline Marban; Franck Dequiedt; Yannick Goumon; Jean-Christophe Paillart; Mathias Mericskay; Ara Parlakian; Pedro Bausero; Wasim Abbas; Georges Herbein; Siavash K Kurdistani; Xavier Grana; Benoit Van Driessche; Christian Schwartz; Ermanno Candolfi; Arndt G Benecke; Carine Van Lint; Olivier Rohr
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-12       Impact factor: 11.205

Review 2.  Chromatin proteins and modifications as drug targets.

Authors:  Kristian Helin; Dashyant Dhanak
Journal:  Nature       Date:  2013-10-24       Impact factor: 49.962

3.  Precise maps of RNA polymerase reveal how promoters direct initiation and pausing.

Authors:  Hojoong Kwak; Nicholas J Fuda; Leighton J Core; John T Lis
Journal:  Science       Date:  2013-02-22       Impact factor: 47.728

Review 4.  Mapping human epigenomes.

Authors:  Chloe M Rivera; Bing Ren
Journal:  Cell       Date:  2013-09-26       Impact factor: 41.582

5.  Inducible re-expression of HEXIM1 causes physiological cardiac hypertrophy in the adult mouse.

Authors:  Monica M Montano; Candida L Desjardins; Yong Qui Doughman; Yee-Hsee Hsieh; Yanduan Hu; Heather M Bensinger; Connie Wang; Julian E Stelzer; Thomas E Dick; Brian D Hoit; Margaret P Chandler; Xin Yu; Michiko Watanabe
Journal:  Cardiovasc Res       Date:  2013-04-11       Impact factor: 10.787

6.  BET bromodomains mediate transcriptional pause release in heart failure.

Authors:  Priti Anand; Jonathan D Brown; Charles Y Lin; Jun Qi; Rongli Zhang; Pedro Calderon Artero; M Amer Alaiti; Jace Bullard; Kareem Alazem; Kenneth B Margulies; Thomas P Cappola; Madeleine Lemieux; Jorge Plutzky; James E Bradner; Saptarsi M Haldar
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

7.  BET acetyl-lysine binding proteins control pathological cardiac hypertrophy.

Authors:  Jessica I Spiltoir; Matthew S Stratton; Maria A Cavasin; Kim Demos-Davies; Brian G Reid; Jun Qi; James E Bradner; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2013-08-09       Impact factor: 5.000

8.  Cardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in mice.

Authors:  Noritada Yoshikawa; Noriaki Shimizu; Takako Maruyama; Motoaki Sano; Tomohiro Matsuhashi; Keiichi Fukuda; Masaharu Kataoka; Toru Satoh; Hidenori Ojima; Takashi Sawai; Chikao Morimoto; Akiko Kuribara; Osamu Hosono; Hirotoshi Tanaka
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

Review 9.  Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes.

Authors:  Geeta J Narlikar; Ramasubramanian Sundaramoorthy; Tom Owen-Hughes
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

Review 10.  A brief review on the Human Encyclopedia of DNA Elements (ENCODE) project.

Authors:  Hongzhu Qu; Xiangdong Fang
Journal:  Genomics Proteomics Bioinformatics       Date:  2013-05-28       Impact factor: 7.691
View more
  20 in total

1.  The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases.

Authors:  Katherine B Schuetze; Keith A Koch; Timothy A McKinsey
Journal:  Future Med Chem       Date:  2016-08-24       Impact factor: 3.808

Review 2.  Epigenetic targets for novel therapies of lung diseases.

Authors:  Brian S Comer; Mariam Ba; Cherie A Singer; William T Gerthoffer
Journal:  Pharmacol Ther       Date:  2014-11-15       Impact factor: 12.310

3.  High-Resolution Chromatin Mapping in Heart Failure: Some Answers, but More Questions.

Authors:  Douglas L Mann
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

Review 4.  Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy.

Authors:  Matthew S Stratton; Timothy A McKinsey
Journal:  Biochem Cell Biol       Date:  2014-12-16       Impact factor: 3.626

5.  Epigenetic therapies in heart failure.

Authors:  Michael Alexanian; Arun Padmanabhan; Timothy A McKinsey; Saptarsi M Haldar
Journal:  J Mol Cell Cardiol       Date:  2019-04-13       Impact factor: 5.000

6.  BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure.

Authors:  Qiming Duan; Sarah McMahon; Priti Anand; Hirsh Shah; Sean Thomas; Hazel T Salunga; Yu Huang; Rongli Zhang; Aarathi Sahadevan; Madeleine E Lemieux; Jonathan D Brown; Deepak Srivastava; James E Bradner; Timothy A McKinsey; Saptarsi M Haldar
Journal:  Sci Transl Med       Date:  2017-05-17       Impact factor: 17.956

Review 7.  Epigenetic regulation in cardiac fibrosis.

Authors:  Li-Ming Yu; Yong Xu
Journal:  World J Cardiol       Date:  2015-11-26

8.  Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA.

Authors:  Matthew S Stratton; Charles Y Lin; Priti Anand; Philip D Tatman; Bradley S Ferguson; Sean T Wickers; Amrut V Ambardekar; Carmen C Sucharov; James E Bradner; Saptarsi M Haldar; Timothy A McKinsey
Journal:  Cell Rep       Date:  2016-07-14       Impact factor: 9.423

9.  BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-κB pathway.

Authors:  Yangli Sun; Jie Huang; Kunpeng Song
Journal:  Exp Ther Med       Date:  2015-10-08       Impact factor: 2.447

Review 10.  BET Protein-Mediated Transcriptional Regulation in Heart Failure.

Authors:  Talha Ijaz; Michael A Burke
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 6.208
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.